Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT03728556 trial: what clinicians have said so far
A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer
- NCT03728556 ↗
- Completed
- CStone Pharmaceuticals
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT03728556 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03728556 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X, typically up to 9 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial of CS1001 as Consolidation Treatment in Subjects With Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer That Has Not Progressed After Prior Concurrent/Sequential Chemoradiotherapy
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Non-Small Cell Lung Cancer Stage III
- Interventions
- CS1001 monoclonal antibody; CS1001 placebo
- Arms
- CS1001monoclonal antibody · Experimental
- CS1001 Placebo · Placebo comparator
- Enrollment
- 381
- Primary outcomes
- Progress Free Survival (PFS)
- Sponsor
- CStone Pharmaceuticals
- Start
- Oct 26, 2018
- Primary completion
- Apr 3, 2023
- Results posted
- No
- Registry record
- NCT03728556 · updated Jun 15, 2023
Publications
linked from the registry- Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, Huang C, Liu A, Yang N, Gong Y, Zhu C, Ma Z, Fang J, Chen G, Zhao J, Shi A, Lin Y, Li G, Liu Y, Wang D, Wu R, Xu X, Shi J, Liu Z, Cui N, Wang J, Wang Q, Zhang R, Yang J, Wu YL. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022 Feb;23(2):209-219. doi: 10.1016/S1470-2045(21)00630-6. Epub 2022 Jan 14. PubMed 35038429